The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

In addition, Paul Stoffels, who led Galapagos’ transformation into a cell therapy company, will retire from his role within ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...